• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
SGMO

SGMO

Sangamo Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.22

+0.01 (+4.76%)

Rating:B-

Company Profile

CEO

Alexander D. Macrae Ch.B

IPO Date

2000-04-06

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.22

Prev. Close

$0.21

Day Low

$0.21

Day High

$0.23

52W Low

$0.10

52W High

$0.77

Market Cap

$0.09B

Volume

0.66M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

19.2%

Avg Negative

12.9%

Avg Neutral

67.9%

News Feed

The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century

InvestorPlace·7/1/2021·↑ positive

CRISPR: 4 Emerging Players

Seeking Alpha·6/30/2021·↑ positive

Sangamo's Hemophilia A Treatment: An Assessment

Seeking Alpha·5/31/2021·↑ positive

Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

Business Wire·5/24/2021·↑ positive

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/4/2021·↓ negative

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research·5/4/2021·↑ positive

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

Business Wire·5/3/2021·↑ positive

Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease

Business Wire·3/17/2021·↑ positive

Sangamo: Partnering A Path To The Future Of Medicine

Seeking Alpha·3/12/2021·↑ positive

Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?

Forbes·3/5/2021·↓ negative